Last reviewed · How we verify
Evolocumab Cartridge
At a glance
| Generic name | Evolocumab Cartridge |
|---|---|
| Also known as | REPATHA |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1 (PHASE4)
- Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Evolocumab Cartridge CI brief — competitive landscape report
- Evolocumab Cartridge updates RSS · CI watch RSS
- NYU Langone Health portfolio CI